265 related articles for article (PubMed ID: 18579112)
1. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.
Kempen JH; Gangaputra S; Daniel E; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Jabs DA; Helzlsouer KJ
Am J Ophthalmol; 2008 Dec; 146(6):802-12.e1. PubMed ID: 18579112
[TBL] [Abstract][Full Text] [Related]
2. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.
Galor A; Jabs DA; Leder HA; Kedhar SR; Dunn JP; Peters GB; Thorne JE
Ophthalmology; 2008 Oct; 115(10):1826-32. PubMed ID: 18579209
[TBL] [Abstract][Full Text] [Related]
3. Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality.
Kempen JH; Newcomb CW; Washington TL; Foster CS; Sobrin L; Thorne JE; Jabs DA; Suhler EB; Rosenbaum JT; Sen HN; Levy-Clarke GA; Nussenblatt RB; Bhatt NP; Lowder CY; Goldstein DA; Leiderman YI; Acharya NR; Holland GN; Read RW; Dunn JP; Dreger KA; Artornsombudh P; Begum HA; Fitzgerald TD; Kothari S; Payal AR; Daniel E; Gangaputra SS; Kaçmaz RO; Liesegang TL; Pujari SS; Khachatryan N; Maghsoudlou A; Suga HK; Pak CM; Helzlsouer KJ; Buchanich JM;
Ophthalmology; 2023 Dec; 130(12):1258-1268. PubMed ID: 37499954
[TBL] [Abstract][Full Text] [Related]
4. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
5. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.
Buggage RR; Levy-Clarke G; Sen HN; Ursea R; Srivastava SK; Suhler EB; Altemare C; Velez G; Ragheb J; Chan CC; Nussenblatt RB; Bamji AT; Sran P; Waldmann T; Thompson DJ
Ocul Immunol Inflamm; 2007; 15(2):63-70. PubMed ID: 17558830
[TBL] [Abstract][Full Text] [Related]
6. Intravenous daclizumab for recalcitrant ocular inflammatory disease.
Bhat P; Castañeda-Cervantes RA; Doctor PP; Foster CS
Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):687-92. PubMed ID: 19198869
[TBL] [Abstract][Full Text] [Related]
7. Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.
Elimelakh M; Dayton V; Park KS; Gruessner AC; Sutherland D; Howe RB; Reding MT; Eastlund T; van Burik JA; Singleton TP; Gruessner RW; Key NS
Haematologica; 2007 Aug; 92(8):1029-36. PubMed ID: 17640860
[TBL] [Abstract][Full Text] [Related]
8. Steroid-free regimen with daclizumab, mycophenolate mofetil, and tacrolimus in liver transplant recipients.
Figueras J; Bernardos A; Prieto M; Gómez M; Rimola A; Ortiz de Urbina J; Cuervas-Mons V; de la Mata M; Dominguez-Granados R
Transplant Proc; 2002 Aug; 34(5):1511-3. PubMed ID: 12176461
[No Abstract] [Full Text] [Related]
9. Immunosuppressive therapy for ocular diseases.
Jap A; Chee SP
Curr Opin Ophthalmol; 2008 Nov; 19(6):535-40. PubMed ID: 18854699
[TBL] [Abstract][Full Text] [Related]
10. Alopecia areata universalis complicating daclizumab therapy for uveitis.
Rosenstein AK; Machler BC; Rosenstein ED
Cutis; 2014 May; 93(5):E13-6. PubMed ID: 24897146
[TBL] [Abstract][Full Text] [Related]
11. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab to prevent rejection after cardiac transplantation.
Hershberger RE; Starling RC; Eisen HJ; Bergh CH; Kormos RL; Love RB; Van Bakel A; Gordon RD; Popat R; Cockey L; Mamelok RD
N Engl J Med; 2005 Jun; 352(26):2705-13. PubMed ID: 15987919
[TBL] [Abstract][Full Text] [Related]
13. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis.
Sobrin L; Christen W; Foster CS
Ophthalmology; 2008 Aug; 115(8):1416-21, 1421.e1. PubMed ID: 18221998
[TBL] [Abstract][Full Text] [Related]
14. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D
Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
[TBL] [Abstract][Full Text] [Related]
15. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.
Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Keenan JD; Rao MM; Ebert CD; Nguyen HH; Kim E; Porco TC; Acharya NR;
JAMA; 2019 Sep; 322(10):936-945. PubMed ID: 31503307
[TBL] [Abstract][Full Text] [Related]
16. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
17. The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants.
Ciancio G; Mattiazzi A; Roth D; Kupin W; Miller J; Burke GW
Clin Transplant; 2003 Oct; 17(5):428-32. PubMed ID: 14703925
[TBL] [Abstract][Full Text] [Related]
18. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of uveitis with immunosuppressives: antimetabolites and alkylating agents].
Caspers-Velu LE
Bull Soc Belge Ophtalmol; 2001; (279):49-59. PubMed ID: 11344715
[TBL] [Abstract][Full Text] [Related]
20. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
Wiseman LR; Faulds D
Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]